Transarterial Therapies for the Treatment of Intrahepatic Cholangiocarcinoma

Zechlinski, Joseph John; Rilling, William S.

doi:10.1055/s-0033-1333650

Cited by 20 publications

(5 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…CCA is often asymptomatic in early stages, and consequently, most patients are diagnosed with advanced unresectable disease burden. The 5-year survival of unresectable CCA is 5% [5]. Risk factors include HBV and HCV infections, hepatolithiasis, nitrosamine compounds, history of primary sclerosing cholangitis and inflammatory bowel disease, and geographic risk factors such as liver fluke infections in southeastern Asia [1].…”

Section: Cholangiocarcinomamentioning

confidence: 99%

A Paradigm Shift in Primary Liver Cancer Therapy Utilizing Genomics, Molecular Biomarkers, and Artificial Intelligence

Moroney

Trivella

George

et al. 2023

Cancers

View full text Add to dashboard Cite

Primary liver cancer is the sixth most common cancer worldwide and the third leading cause of cancer-related death. Conventional therapies offer limited survival benefit despite improvements in locoregional liver-directed therapies, which highlights the underlying complexity of liver cancers. This review explores the latest research in primary liver cancer therapies, focusing on developments in genomics, molecular biomarkers, and artificial intelligence. Attention is also given to ongoing research and future directions of immunotherapy and locoregional therapies of primary liver cancers.

show abstract

Section: Cholangiocarcinomamentioning

confidence: 99%

A Paradigm Shift in Primary Liver Cancer Therapy Utilizing Genomics, Molecular Biomarkers, and Artificial Intelligence

Moroney

Trivella

George

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…Dokudaki ortalama menzili 2,5 mm olup maksimum menzil 12 mm'dir. En büyük avantajı, eksternal radyasyon uygulamalarına kıyasla çok daha yüksek lokal dozlara ulaşan, örneğin 120 Gy'lik hedef dozlara ulaşılabilmesidir (16).…”

Section: Y-90radyoembolizasyonunclassified

Treatment of Intrahepatic Cholangiocellular Carcinoma with Y-90 Labelled Microspheres

Balli¹

2019

nts

View full text Add to dashboard Cite

Intrahepatic cholangiocellular carcinoma (ICC) is a rapidly progressive malignancy of intrahepatic bile duct epithelium. ICC is the second most common primary malignant tumor of the liver which accounts for 10% to 20% of primary liver tumors. At the present time, surgery has been accepted as the only potential curative treatment method, however, only 30% of patients are eligible for surgical treatment because of anatomical situations, insufficient liver reserve, or concomitant comorbidities. For ICC patients who are ineligible for surgical treatments, therapies like systemic chemotherapy, thermal or nonthermal ablations, and external radiotherapy are applied as an initial treatment. In addition, less side effects advantage over systemic chemotherapy, yttrium-90 marked microsphere treatment has been prominent especially in the last years. The majority of the recent studies have proved the effectivity of yttrium-90 labelled microsphere treatment in ICC and accepted this treatment as a safe treatment. However, the variability of the patients' demographical features in these studies leads to different outcomes which is thought to be as a result of individual and biological discrepancies.

show abstract

“…Currently, different local therapies are available for inoperable ICC. The role of trans-arterial chemo-embolization (TACE) has been investigated ( 9 ). A meta-analysis on TACE in ICC treatment has been recently published, demonstrating a survival benefit compared to standard systemic therapies, with a good toxicity profile ( 10 ) Similarly, radiofrequency ablation resulted an effective treatment option in unresectable ICC.…”

Section: Introductionmentioning

confidence: 99%

Stereotactic radiotherapy in intrahepatic cholangiocarcinoma: A systematic review

et al. 2021

View full text Add to dashboard Cite

Among biliary tract cancers, intrahepatic cholangiocarcinoma (ICC) has different characteristics compared with those in other sites. Current guidelines suggest several treatment options for ICC, including stereotactic body radiation therapy (SBRT). However, the role of SBRT in locally advanced ICC is unclear. The aim of the present study was to present a systematic review on the efficacy and safety of SBRT in ICC. A systematic review based on the PRISMA methodology was performed. Only papers reporting outcomes in terms of overall survival (OS) after SBRT in inoperable patients with ICC were included. Secondary aims were local control (LC), progression-free survival (PFS) and treatment-related toxicity. Six papers (145 patients) were included in the present analysis. SBRT was frequently used as a salvage treatment, since 28.6-66.7% of patients received previous systemic or local treatments. The median SBRT dose was 45 Gy delivered in 3-5 fractions. The median follow-up was 16 months, and median OS time was 14 months (range, 10-48 months). In one of the included studies, SBRT was significantly superior in terms of OS compared with both chemoradiation and trans-arterial-radio-embolization. The 1-year LC rate was 85% in one study, and 1-year PFS rates were 50 and 68% in two studies, respectively. Toxicity was generally not reported in detail or was reported including other sites of biliary cancers. Overall, limited evidence was available on the efficacy of SBRT in ICC, which should be further investigated in prospective studies with a larger number of patients. However, based on the available data, SBRT seems to produce similar results compared with other ICC treatments, with the advantage of being a very short and non-invasive therapy. Therefore, SBRT should be considered in selected patients with ICC.

show abstract

Transarterial Therapies for the Treatment of Intrahepatic Cholangiocarcinoma

Cited by 20 publications

References 31 publications

A Paradigm Shift in Primary Liver Cancer Therapy Utilizing Genomics, Molecular Biomarkers, and Artificial Intelligence

A Paradigm Shift in Primary Liver Cancer Therapy Utilizing Genomics, Molecular Biomarkers, and Artificial Intelligence

Treatment of Intrahepatic Cholangiocellular Carcinoma with Y-90 Labelled Microspheres

Stereotactic radiotherapy in intrahepatic cholangiocarcinoma: A systematic review

Contact Info

Product

Resources

About